Dr Jana Combrinck, GP, and Dr Kym Jones, Gynaecologist, Joondalup
Attending the 19th Annual IMS Congress last year, we gained insights into the latest developments in menopause
Breast cancer risk is one of the most common concerns expressed by both patients and healthcare practitioners when discussing menopausal hormone therapy (MHT).
Professor Robert Langer, one of the principal investigators of the Women’s Health Initiative (WHI) trial, helped clarify several misconceptions about MHT. The WHI study, which contributed to widespread fear, suggested that oestrogen and progestin (CEE+MPA) increased breast cancer risk....
Attending the 19th Annual IMS Congress last year, we gained insights into the latest developments in menopause
Breast cancer risk is one of the most common concerns expressed by both patients and healthcare practitioners when discussing menopausal hormone therapy (MHT).
Professor Robert Langer, one of the principal investigators of the Women’s Health Initiative (WHI) trial, helped clarify several misconceptions about MHT. The WHI study, which contributed to widespread fear, suggested that oestrogen and progestin (CEE+MPA) increased breast cancer risk....
This content is restricted to Medical Forum readers; this is a new feature. If you haven’t registered with our site in the last few weeks, please create a new account below. If you have subscribed, please log in.